Retinopathy of prematurity

Last updated

Retinopathy of prematurity
Other namesTerry syndrome, [1] retrolental fibroplasia (RLF)
Specialty Ophthalmology   OOjs UI icon edit-ltr-progressive.svg

Retinopathy of prematurity (ROP), also called retrolental fibroplasia (RLF) and Terry syndrome, is a disease of the eye affecting prematurely born babies generally having received neonatal intensive care, in which oxygen therapy is used because of the premature development of their lungs. [2] It is thought to be caused by disorganized growth of retinal blood vessels and may result in scarring and retinal detachment. ROP can be mild and may resolve spontaneously, but it may lead to blindness in serious cases. Thus, all preterm babies are at risk for ROP, and very low birth-weight is an additional risk factor. Both oxygen toxicity and relative hypoxia can contribute to the development of ROP.

Contents

Causes

By the fourth month of pregnancy, the fetal retina has begun to develop vascularization. Such formation of blood vessels appears to be very sensitive to the amount of oxygen supplied, either naturally or artificially. In rare cases ROP has been found in some patients with a mutation in the NDP gene, which is normally associated with the more damaging Norrie disease. [3] [4] [5]

Risk factors

Various risk factors contribute to the development of ROP. They are:

Pathophysiology

During development, blood vessels grow from the central part of the retina outwards. This process is completed a few weeks before the normal time of delivery. However, in premature babies it is incomplete. If blood vessels grow normally, ROP does not occur. If the vessels grow and branch abnormally the baby develops ROP. These abnormal blood vessels may grow up from the plane of the retina and may bleed inside the eye. When the blood and abnormal vessels are reabsorbed, it may give rise to multiple band like membranes which can pull up the retina, causing detachment of the retina and eventually blindness before six months.[ citation needed ]

Normally, maturation of the retina proceeds in utero, and at term, the medial portion (nasal retina) of the retina is fully vascularized, while the lateral portion (temporal retina) is only incompletely vascularized. [7] The normal growth of the blood vessels is directed to relatively low-oxygen areas of the retina, but the vessels remain in the plane of the retina and do not grow into the vitreous humor. If excess oxygen is given, normal blood vessels degrade and cease to develop. When the excess oxygen environment is removed, the blood vessels rapidly begin forming again and grow into the vitreous humor of the eye from the retina. [7] [8]

The key disease element in ROP is fibrovascular proliferation. This is growth of abnormal new vessels; this may regress, but frequently progresses. Associated with the growth of these new vessels is fibrous tissue (scar tissue) that may contract to cause retinal detachment. Multiple factors can determine whether the disease progresses, including overall health, birth weight, the stage of ROP at initial diagnosis, and the presence or absence of "plus disease". Supplemental oxygen exposure, while a risk factor, is not the main risk factor for development of this disease. Restricting supplemental oxygen use reduces the rate of ROP, but may raise the risk of other hypoxia-related systemic complications, including death. [9]

Patients with ROP, particularly those who have developed severe disease needing treatment are at greater risk for strabismus, glaucoma, cataracts and shortsightedness (myopia) later in life and should be examined yearly to help prevent or detect and treat these conditions.

Diagnosis

The stages of ROP disease have been defined by the International Classification of Retinopathy of Prematurity (ICROP).

In older patients, the appearance of the disease is less well described but includes the residua of the ICROP stages as well as secondary retinal responses.

International classification

The system used for describing the findings of active ROP is entitled The International Classification of Retinopathy of Prematurity (ICROP). [10] ICROP uses a number of parameters to describe the disease. They are location (zone) of the disease, the circumferential extent of the disease based on the clock hours, the severity (stage) of the disease and the presence or absence of "Plus Disease". Each aspect of the classification has a technical definition. This classification was used for the major clinical trials. It was revised in 2005. [11]

Zones of the retina in ROP ROP zones.jpg
Zones of the retina in ROP

The zones are centered on the optic nerve. Zone I is the posterior zone of the retina, defined as the circle with a radius extending from the optic nerve to double the distance to the macula. Zone II is an annulus with the inner border defined by zone I and the outer border defined by the radius defined as the distance from the optic nerve to the nasal ora serrata. Zone III is the residual temporal crescent of the retina.

The circumferential extent of the disease is described in segments as if the top of the eye were 12 on the face of an analog clock, e.g. stage 1 from 4:00 to 7:00. (The extent is a bit less important since the treatment indications from the Early Treatment for ROP.) [12]

The Stages describe the ophthalmoscopic findings at the junction between the vascularized and avascular retina.

Plus disease

Plus disease can be present as a major complicating factor at any stage. It is characterised by:

Differential diagnosis

The most difficult aspect of the differential diagnosis may arise from the similarity of two other diseases:

Screening

Almost all infants with ROP have a gestational age of 31 weeks or less (regardless of birth weight) or a birth weight of 1250 g (2.76 lbs) or less; these indications are generally used to decide whether a baby should be screened for ROP, but some centres, especially in developing countries, extend birth weight screening criteria to 1500 g (3.3 lbs). [14]

Any premature baby with severe illness in perinatal period (respiratory distress syndrome, sepsis, blood transfusion, intraventricular haemorrhage, apnoeic episodes, etc.) may also be offered ROP screening.

Timing

Retinal examination with scleral depression is generally recommended for patients born before 30–32 weeks gestation, or 4–6 weeks of life, whichever is later. It is then repeated every 1–3 weeks until vascularization is complete (or until disease progression mandates treatment).

Procedure

Following pupillary dilation using eye drops, the retina is examined using a special lighted instrument (an indirect ophthalmoscope). The peripheral portions of the retina are sometimes pushed into view using scleral depression. Examination of the retina of a premature infant is performed to determine how far the retinal blood vessels have grown (the zone), and whether or not the vessels are growing flat along the wall of the eye (the stage). This eye examination has been shown to be painful and the use of adequate analgesia during the procedure is advised. [15] Once the vessels have grown into zone III (see below) it is usually safe to discharge the child from further screening for ROP. The stage of ROP refers to the character of the leading edge of growing retinal blood vessels (at the vascular-avascular border).

Monitoring

In order to allow timely intervention, a system of monitoring is undertaken for infants at risk of developing ROP. These monitoring protocols differ geographically because the definition of high-risk is not uniform or perfectly defined. In the USA the consensus statement of experts is informed by data derived by clinical trials and published in Pediatrics 2006. They included infants with birthweights under 1500 grams or under 30 weeks gestation in most cases. The first examination should take place within the first 4 weeks of birth, and regular, weekly examination is required until it is clear that the eyes are not going to develop disease needing treatment, or one or both eyes develop disease requiring treatment. Treatment should be administered within a 48 hours, as the condition can progress rapidly.

Management

Treatment

The retina (red) is detached at the top of the eye. Human eye cross section detached retina.svg
The retina (red) is detached at the top of the eye.
The silicone band (scleral buckle, blue) is placed around the eye. This brings the wall of the eye into contact with the detached retina, allowing the retina to re-attach. Human eye cross section scleral buckle.svg
The silicone band (scleral buckle, blue) is placed around the eye. This brings the wall of the eye into contact with the detached retina, allowing the retina to re-attach.

Follow-up

Prognosis

Stages 1 and 2 do not lead to blindness. However, they can progress to the more severe stages. Threshold disease is defined as disease that has a 50% likelihood of progressing to retinal detachment. Threshold disease is considered to be present when stage 3 ROP is present in either zone I or zone II, with at least five continuous or eight total clock hours of disease, and the presence of plus disease. [22] Progression to stage 4 (partial retinal detachment), or to stage 5 (total retinal detachment), will result in substantial or total loss of vision for the infant.

Epidemiology

ROP prevalence varies, from 5 to 8% in developed countries with adequate neonatological facilities, to up to 30% in middle-income developing countries. [24]

There is increasing evidence that ROP and blindness due to ROP are now public health problems in the middle income countries of Latin America, Eastern Europe and the more advanced economies in South East Asia and the Middle east region. In these countries ROP is often the most common cause of blindness in children. [25] [26] ROP is highly likely to become an increasing problem in India, China and other countries in Asia as these countries expand the provision of services for premature infants.

There is also evidence that the population of premature infants at risk of severe ROP varies depending on the level of neonatal intensive care being provided. [25] In countries with high development indices and very low neonatal mortality rates (e.g. North America, Western Europe), severe ROP is generally limited to extremely preterm infants i.e. those weighing less than 1 kg (2.2 lbs) at birth. At the other end of the development spectrum, countries with very low development indices and very high neonatal mortality rates (e.g. much of subSaharan Africa) ROP is rare as most premature babies do not have access to neonatal intensive care and so do not survive. Countries with moderate development indices are improving access to neonatal intensive care, and in these settings bigger, more mature babies are also at risk of severe ROP as neonatal care may be suboptimal. These findings have two main implications: firstly, much can be done in countries with moderate development indices to improve neonatal care, to reduce the risk of severe ROP in bigger babies and increase survival of extremely preterm infants, and secondly, in these settings bigger more mature babies need to be included in ROP programs and examined regularly so as to detect those babies developing ROP requiring treatment.

In 2012, the World Health Organization published data on rates of preterm birth and the number of premature babies born in different regions of the world. [27] This report contained three main findings:

History

This disease was first described in a premature baby in 1942 as reported by Theodore L. Terry. [28] Between 1941 and 1953, over 12,000 babies worldwide were affected by it. However, Dr Kate Isabel Campbell (1889–1986), a specialist in children's diseases, was actually responsible in 1951 for proving the link between retrolental fibroplasia (a blindness in premature babies) and oxygen levels in humidicribs. [29]

Soul musician Stevie Wonder, actor Tom Sullivan, pianist Derek Paravicini, and jazz singer Diane Schuur, singer Gilbert Montagné are a few famous people who have the disease. The first case of the epidemic was seen on St. Valentine's Day in 1941 when a premature baby in Boston was diagnosed. Cases were then seen all over the world and the cause was, at that point, unknown. By 1951 a clear link between incidence and affluence became clear: many cases were seen in developed countries with organized and well-funded health care. Two British scientists suggested that it was oxygen toxicity that caused the disease. Babies born prematurely in such affluent areas were treated in incubators which had artificially high levels of oxygen. Studies on rats made this cause seem more likely, but the link was eventually confirmed by a controversial study undertaken by American pediatricians. The study involved two groups of babies. Some [30] were given the usual oxygen concentrations in their incubators, while the other group had "curtailed" oxygen levels. The latter group was shown to have a lower incidence of the disease. As a result, oxygen levels in incubators were lowered and consequently, the epidemic was halted. [31]

Related Research Articles

<span class="mw-page-title-main">Retinopathy</span> Medical condition

Retinopathy is any damage to the retina of the eyes, which may cause vision impairment. Retinopathy often refers to retinal vascular disease, or damage to the retina caused by abnormal blood flow. Age-related macular degeneration is technically included under the umbrella term retinopathy but is often discussed as a separate entity. Retinopathy, or retinal vascular disease, can be broadly categorized into proliferative and non-proliferative types. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. Diabetes is the most common cause of retinopathy in the U.S. as of 2008. Diabetic retinopathy is the leading cause of blindness in working-aged people. It accounts for about 5% of blindness worldwide and is designated a priority eye disease by the World Health Organization.

<span class="mw-page-title-main">Diabetic retinopathy</span> Medical condition

Diabetic retinopathy, is a medical condition in which damage occurs to the retina due to diabetes mellitus. It is a leading cause of blindness in developed countries.

The National Eye Institute (NEI) is part of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NEI is "to eliminate vision loss and improve quality of life through vision research." NEI consists of two major branches for research: an extramural branch that funds studies outside NIH and an intramural branch that funds research on the NIH campus in Bethesda, Maryland. Most of the NEI budget funds extramural research.

<span class="mw-page-title-main">Oxygen toxicity</span> Toxic effects of breathing oxygen at high partial pressures

Oxygen toxicity is a condition resulting from the harmful effects of breathing molecular oxygen at increased partial pressures. Severe cases can result in cell damage and death, with effects most often seen in the central nervous system, lungs, and eyes. Historically, the central nervous system condition was called the Paul Bert effect, and the pulmonary condition the Lorrain Smith effect, after the researchers who pioneered the discoveries and descriptions in the late 19th century. Oxygen toxicity is a concern for underwater divers, those on high concentrations of supplemental oxygen, and those undergoing hyperbaric oxygen therapy.

<span class="mw-page-title-main">Macular edema</span> Medical condition

Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye and causes it to thicken and swell (edema). The swelling may distort a person's central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view.

<span class="mw-page-title-main">Retinal detachment</span> Medical condition of the eye

Retinal detachment is a disorder of the eye in which the retina peels away from its underlying layer of support tissue. Initial detachment may be localized, but without rapid treatment the entire retina may detach, leading to vision loss and blindness. It is a surgical emergency.

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Retinal hemorrhage is a disorder of the eye in which bleeding occurs in the retina, the light sensitive tissue, located on the back wall of the eye. There are photoreceptor cells in the retina called rods and cones, which transduce light energy into nerve signals that can be processed by the brain to form visual images. Retinal hemorrhage is strongly associated with child abuse in infants and young children and often leaves such abused infants permanently blind. In older children and adults, retinal hemorrhage can be caused by several medical conditions such as hypertension, retinal vein occlusion, anemia, leukemia or diabetes.

Neovascularization is the natural formation of new blood vessels, usually in the form of functional microvascular networks, capable of perfusion by red blood cells, that form to serve as collateral circulation in response to local poor perfusion or ischemia.

Eales disease is a type of obliterative vasculopathy, also known as angiopathia retinae juvenilis, periphlebitis retinae or primary perivasculitis of the retina. It was first described by the British ophthalmologist Henry Eales (1852–1913) in 1880 and is a rare ocular disease characterized by inflammation and possible blockage of retinal blood vessels, abnormal growth of new blood vessels (neovascularization), and recurrent retinal and vitreal hemorrhages.

<span class="mw-page-title-main">Intravitreal administration</span>

Intravitreal is a route of administration of a drug, or other substance, in which the substance is delivered into the vitreous humor of the eye. "Intravitreal" literally means "inside an eye". Intravitreal injections were first introduced in 1911 when Ohm gave an injection of air into the vitreous humor to repair a detached retina. In the mid-1940s, intravitreal injections became a standard way to administer drugs to treat endophthalmitis and cytomegalovirus retinitis.

Rubeosis iridis is a medical condition of the iris of the eye in which new abnormal blood vessels are found on the surface of the iris.

<span class="mw-page-title-main">Macular telangiectasia</span> Disease of the retina affecting central vision

Macular telangiectasia is a condition of the retina, the light-sensing tissue at the back of the eye that causes gradual deterioration of central vision, interfering with tasks such as reading and driving.

<span class="mw-page-title-main">Familial exudative vitreoretinopathy</span> Retinal vascular disease

Familial exudative vitreoretinopathy is a genetic disorder affecting the growth and development of blood vessels in the retina of the eye. This disease can lead to visual impairment and sometimes complete blindness in one or both eyes. FEVR is characterized by incomplete vascularization of the peripheral retina. This can lead to the growth of new blood vessels which are prone to leakage and hemorrhage and can cause retinal folds, tears, and detachments. Treatment involves laser photocoagulation of the avascular portions of the retina to reduce new blood vessel growth and risk of complications including leakage of retinal blood vessels and retinal detachments.

<span class="mw-page-title-main">Branch retinal vein occlusion</span> Medical condition

Branch retinal vein occlusion is a common retinal vascular disease of the elderly. It is caused by the occlusion of one of the branches of central retinal vein.

<span class="mw-page-title-main">Radiation retinopathy</span> Medical condition

Radiation retinopathy is damage to retina due to exposure to ionizing radiation. Radiation retinopathy has a delayed onset, typically after months or years of radiation, and is slowly progressive. In general, radiation retinopathy is seen around 18 months after treatment with external-beam radiation and with brachytherapy. The time of onset of radiation retinopathy is between 6 months to 3 years.

<span class="mw-page-title-main">Childhood blindness</span> Medical condition

Childhood blindness is an important contribution to the national prevalence of the disability of blindness. Blindness in children can be defined as a visual acuity of <3/60 in the eye with better vision of a child under 16 years of age. This generally means that the child cannot see an object 10 feet away, that another child could see if it was 200 feet away.

<span class="mw-page-title-main">Intravitreal injection</span> Method of administration of drugs into the eye by injection with a fine needle

Intravitreal injection is the method of administration of drugs into the eye by injection with a fine needle. The medication will be directly applied into the vitreous humor. It is used to treat various eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and infections inside the eye such as endophthalmitis. As compared to topical administration, this method is beneficial for a more localized delivery of medications to the targeted site, as the needle can directly pass through the anatomical eye barrier and dynamic barrier. It could also minimize adverse drug effects on other body tissues via the systemic circulation, which could be a possible risk for intravenous injection of medications. Although there are risks of infections or other complications, with suitable precautions throughout the injection process, chances for these complications could be lowered.

Sickle cell retinopathy can be defined as retinal changes due to blood vessel damage in the eye of a person with a background of sickle cell disease. It can likely progress to loss of vision in late stages due to vitreous hemorrhage or retinal detachment. Sickle cell disease is a structural red blood cell disorder leading to consequences in multiple systems. It is characterized by chronic red blood cell destruction, vascular injury, and tissue ischemia causing damage to the brain, eyes, heart, lungs, kidneys, spleen, and musculoskeletal system.

Cynthia Ann Toth is an American ophthalmologist who is Distinguished Professor of Ophthalmology at Duke University. Toth has pioneered the use of optical coherence tomography to better understand, diagnose and treat macular disease. She was awarded the 2021 Retina Research Foundation Pyron Award.

References

  1. ↑ "Terry Syndrome". Stedman's Medical Dictionary. Lippincott Williams & Wilkins. 2006.
  2. ↑ Yulia DE, Soeharto DA (December 2022). "One year follow-up of intravitreal bevacizumab injection in Aggressive Retinopathy of Prematurity at Indonesian national referral hospital: Case series". Annals of Medicine and Surgery. 84: 104853. doi:10.1016/j.amsu.2022.104853. PMC   9758374 . PMID   36536703.
  3. ↑ Shastry BS, Pendergast SD, Hartzer MK, Liu X, Trese MT (May 1997). "Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity". Archives of Ophthalmology. 115 (5): 651–655. doi:10.1001/archopht.1997.01100150653015. PMID   9152134.
  4. ↑ Dickinson JL, Sale MM, Passmore A, FitzGerald LM, Wheatley CM, Burdon KP, et al. (September–October 2006). "Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity". Clinical & Experimental Ophthalmology. 34 (7): 682–688. doi:10.1111/j.1442-9071.2006.01314.x. PMID   16970763. S2CID   43683713.
  5. ↑ Shastry BS (August 2010). "Genetic susceptibility to advanced retinopathy of prematurity (ROP)". Journal of Biomedical Science. 17 (1): 69. doi: 10.1186/1423-0127-17-69 . PMC   2933676 . PMID   20738858.
  6. ↑ Karna P, Muttineni J, Angell L, Karmaus W (June 2005). "Retinopathy of prematurity and risk factors: a prospective cohort study". BMC Pediatrics. 5 (1): 18. doi: 10.1186/1471-2431-5-18 . PMC   1175091 . PMID   15985170.
  7. 1 2 Kumar V (2007). "Chapter 29: Eye, Retina and Vitreous, Retinal Vascular Disease". Robbins basic pathology (8th ed.). Philadelphia: Saunders/Elsevier. ISBN   978-1416029731.
  8. ↑ Guyton A, Hall J (2006). "Chapter 17: Local and Humoral Control of Blood Flow by the Tissues". In Rebecca G (ed.). Textbook of Medical Physiology (Book) (11th ed.). Philadelphia, Pennsylvania: Elsevier Inc. p. 200. ISBN   978-0-7216-0240-0.
  9. ↑ Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszczak E, Askie L, et al. (May 2013). "Oxygen saturation and outcomes in preterm infants". The New England Journal of Medicine. 368 (22): 2094–2104. doi: 10.1056/nejmoa1302298 . PMID   23642047. S2CID   205095545.
  10. ↑ Committee for the Classification of Retinopathy of Prematurity (August 1984). "An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity". Archives of Ophthalmology. 102 (8): 1130–1134. doi:10.1001/archopht.1984.01040030908011. PMID   6547831.
  11. ↑ Committee for the Classification of Retinopathy of Prematurity (July 2005). "The International Classification of Retinopathy of Prematurity revisited". Archives of Ophthalmology. 123 (7): 991–999. doi: 10.1001/archopht.123.7.991 . PMID   16009843.
  12. ↑ Early Treatment for Retinopathy of Prematurity Cooperative Group (December 2003). "Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial". Archives of Ophthalmology. 121 (12): 1684–1694. doi: 10.1001/archopht.121.12.1684 . PMID   14662586.
  13. 1 2 3 4 Retinopathy of Prematurity at eMedicine
  14. ↑ Jefferies A (December 2010). "Retinopathy of prematurity: Recommendations for screening". Paediatrics & Child Health. 15 (10): 667–674. doi:10.1093/pch/15.10.667. PMC   3006218 . PMID   22131866.
  15. ↑ Avila-Alvarez, Alejandro; Pertega-Diaz, Sonia; Vazquez Gomez, Lorena; Sucasas Alonso, Andrea; Romero Rey, Henar; Eiriz Barbeito, Dolores; Cabana Vazquez, Montserrat (2020). "Pain assessment during eye examination for retinopathy of prematurity screening: Skin conductance versus PIPP-R". Acta Paediatrica. 109 (5): 935–942. doi:10.1111/apa.15066. PMID   31630433. S2CID   204813261.
  16. ↑ Dobson V, Quinn GE, Summers CG, Hardy RJ, Tung B, Good WV (July 2011). "Grating visual acuity results in the early treatment for retinopathy of prematurity study". Archives of Ophthalmology. 129 (7): 840–846. doi:10.1001/archophthalmol.2011.143. PMC   4374597 . PMID   21746974.
  17. ↑ Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K (2007). "Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity". Indian Journal of Ophthalmology. 55 (1): 75–76. doi: 10.4103/0301-4738.29505 . PMID   17189897.
  18. ↑ Mintz-Hittner HA, Kennedy KA, Chuang AZ (February 2011). "Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity". The New England Journal of Medicine. 364 (7): 603–615. doi:10.1056/NEJMoa1007374. PMC   3119530 . PMID   21323540.
  19. ↑ Sankar MJ, Sankar J, Chandra P (January 2018). "Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity". The Cochrane Database of Systematic Reviews. 1 (1): CD009734. doi:10.1002/14651858.CD009734.pub3. PMC   6491066 . PMID   29308602.
  20. ↑ Filippi L (2013). J Pediatr. 2013 Dec;163(6):1570-1577.e6
  21. ↑ Ristori C (2011). Invest Ophthalmol Vis Sci. 2011 Jan 5;52(1):155-70.
  22. ↑ Phelps DL (2001). "Retinopathy of Prematurity: History, Classification, and Pathophysiology". NeoReviews. 2 (7): e153–e166. doi:10.1542/neo.2-7-e153.
  23. ↑ Heidary F, Gharebaghi R (2016). "Outcomes of Retinopathy of Prematurity". Medical Hypothesis, Discovery & Innovation in Ophthalmology Journal. 5 (4): 112–114. PMC   5346299 . PMID   28293657.
  24. ↑ Gergely K, Gerinec A (2010). "Retinopathy of prematurity--epidemics, incidence, prevalence, blindness". Bratislavske Lekarske Listy. 111 (9): 514–517. PMID   21180268.
  25. 1 2 Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A (May 2005). "Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs". Pediatrics. 115 (5): e518–e525. doi: 10.1542/peds.2004-1180 . PMID   15805336.
  26. ↑ Limburg H, Gilbert C, Hon DN, Dung NC, Hoang TH (February 2012). "Prevalence and causes of blindness in children in Vietnam". Ophthalmology. 119 (2): 355–361. doi:10.1016/j.ophtha.2011.07.037. PMID   22035577.
  27. ↑ "Born Too Soon: The Global Action Report on Preterm Birth". World Health Organization. 2012. Retrieved 9 June 2013.
  28. ↑ Lambert SR, Lyons CJ (31 October 2016). Taylor and Hoyt's pediatric ophthalmology and strabismus (Fifth ed.). Edinburgh. ISBN   9780702066160. OCLC   960162637.{{cite book}}: CS1 maint: location missing publisher (link)
  29. ↑ National Foundation for Australian Women and The University of Melbourne. "Campbell, Kate Isabel - Woman - The Australian Women's Register". www.womenaustralia.info. Retrieved 3 November 2022.
  30. ↑ Silverman WA (November 1980). Retrolental fibroplasia: a modern parable. Grune & Stratton. ISBN   9780808912644 . Retrieved 21 September 2013.
  31. ↑ Silverman WA (November 1980). Retrolental fibroplasia: a modern parable. Grune & Stratton. ISBN   9780808912644 . Retrieved 21 September 2013. Chapter 8: "The Consequences of Oxygen Restriction"
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.